CDP 571 engineered human antibody targeted to tumor necrosis factor data

CTP (Slough, U.K.) reported Phase II results of CDP 571, with reduced symptoms and good toleration of the antibody.

As presented at the European Gastroenterology Week meeting in Berlin, 15 patients with mild to moderate ulcerative colitis, who were unresponsive to steroids, or relapsed, were injected with 5 mg/kg and followed for eight weeks. ...